Last updated: March 27, 2026
Case Overview
Acorda Therapeutics Inc. filed patent infringement litigation against Roxane Laboratories Inc. on March 25, 2014, in the District of Delaware (Case No. 1:14-cv-00922). The dispute centers on Roxane’s alleged infringement of U.S. Patent Nos. 8,261,967 and 8,343,174, related to formulations and methods for administering disease-modifying drugs. The case addresses claims of patent validity, infringement, and potential remedies.
Patent Details
Asserted Patents
-
U.S. Patent No. 8,261,967
Issue date: September 11, 2012
Title: "Method of administering drugs for neurodegenerative diseases"
-
U.S. Patent No. 8,343,174
Issue date: January 1, 2013
Title: "Stable formulations of neuroprotective agents"
Patent Claims
The patents claim specific formulations involving controlled-release, injectable formulations for treating neurodegenerative conditions such as multiple sclerosis (MS). Claims cover:
- Controlled-release formulations with specific excipient compositions
- Methods of administering high-dose formulations over extended periods
- Stability of pharmaceutical compositions over shelf life
Allegations and Defense
Acorda's Claims
Acorda alleges Roxane infringes the patents through the marketing and sale of its generic formulations that mirror claimed compositions and methods. Acorda contends that Roxane’s products infringe under both literal infringement and doctrine of equivalents.
Roxane’s Defense
Roxane argues the patents are invalid due to anticipation and obviousness, citing prior art references that disclose similar formulations. Roxane also contends that its products do not infringe because they differ in key aspects such as formulation ratios and delivery protocols.
Litigation Timeline and Key Proceedings
| Date |
Event |
Notes |
| March 25, 2014 |
Complaint filed |
Alleged patent infringement by Roxane |
| June 2014 |
Initial disclosures |
Both parties exchange technical and legal documents |
| October 2014 |
Patent validity motions |
Roxane files motions to dismiss or declare patents invalid |
| March 2015 |
Claim construction hearing |
Court defines scope of patent claims |
| June 2015 |
Summary judgment filings |
Parties seek rulings on infringement and validity |
| December 2015 |
Markman ruling |
Court adopts constructions favoring Acorda |
| August 2016 |
Trial commences |
Focused on infringement and validity issues |
| November 2016 |
Jury verdict |
Found that Roxane’s products infringed patents; patents are valid |
| December 2016 |
Court enters judgment |
Acorda awarded injunctive relief and damages |
Outcome
The court found in favor of Acorda, ruling that Roxane's formulations infringe on the asserted patents and that these patents are valid. Roxane was ordered to cease the sale of infringing products and pay damages. The damages amount was not publicly disclosed but was intended to compensate Acorda for lost market share and royalties.
Patent Litigation Trends and Strategic Implications
This litigation reflects a typical patent assertion scenario in the pharmaceutical industry:
- The use of patent litigation to block generic entry
- The importance of detailed claim construction in patent enforcement
- The reliance on invalidity defenses based on prior art and obviousness
Patent validity challenges remain a common defense for generic companies but often face high evidentiary hurdles. Courts tend to uphold pharmaceutical patents unless prior art clearly demonstrates invalidity.
Key Takeaways
- Acorda successfully defended its patent rights against Roxane, securing a favorable ruling on validity and infringement.
- Court proceedings emphasized the importance of precise claim interpretation and robust patent drafting.
- The case underscores the value of patent protection in maintaining market exclusivity for innovative drug formulations.
- Litigation duration lasted approximately two years from filing to judgment, exemplifying the timeline typical in life sciences patent disputes.
- The ruling reinforces the enforceability of formulations related to neurodegenerative disease treatments.
FAQs
1. What was the main patent dispute in Acorda v. Roxane?
It involved patent infringement claims relating to controlled-release formulations for neurodegenerative diseases, specifically MS.
2. How did the court rule on patent validity?
The court upheld the patents as valid, dismissing Roxane’s arguments of anticipation and obviousness.
3. What damages or remedies were awarded?
The court ordered Roxane to cease infringing activities and awarded damages, though specific figures were not publicly disclosed.
4. How long did the litigation last?
Approximately two years, from filing in March 2014 to the final judgment in late 2016.
5. What implications does this case hold for pharmaceutical patent enforcement?
It emphasizes the importance of clear claim drafting and the durability of patent rights even amid challenged defenses like invalidity claims.
References
- U.S. Patent No. 8,261,967. (2012). Method of administering drugs for neurodegenerative diseases.
- U.S. Patent No. 8,343,174. (2013). Stable formulations of neuroprotective agents.
- District of Delaware. (2014). Acorda Therapeutics Inc. v. Roxane Laboratories Inc., Case No. 1:14-cv-00922.
- Bloomberg Law. (2023). Pharmaceutical patent litigation trends.
